Moreover, when MPS II fibroblasts were treated with an enzyme used in enzyme replacement therapy for this MPS type, human recombinant iduronate-2-sulfatase (Elaprase), to normalize GAG levels in cells, the effects of changes in levels of THBS1 and OXTR transcripts were reversed (Figure 8) which again supported the above conclusion. This evidence concerns the gene OXTR and mucopolysaccharidosis.